Kimia Farma Tbk PT
IDX:KAEF

Watchlist Manager
Kimia Farma Tbk PT Logo
Kimia Farma Tbk PT
IDX:KAEF
Watchlist
Price: 600 IDR Market Closed
Market Cap: 3.3T IDR
Have any thoughts about
Kimia Farma Tbk PT?
Write Note

Kimia Farma Tbk PT
Accrued Liabilities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Kimia Farma Tbk PT
Accrued Liabilities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Accrued Liabilities CAGR 3Y CAGR 5Y CAGR 10Y
Kimia Farma Tbk PT
IDX:KAEF
Accrued Liabilities
Rp513.5B
CAGR 3-Years
59%
CAGR 5-Years
28%
CAGR 10-Years
24%
T
Tempo Scan Pacific Tbk PT
IDX:TSPC
Accrued Liabilities
Rp146B
CAGR 3-Years
19%
CAGR 5-Years
8%
CAGR 10-Years
4%
Kalbe Farma Tbk PT
IDX:KLBF
Accrued Liabilities
Rp782.7B
CAGR 3-Years
2%
CAGR 5-Years
9%
CAGR 10-Years
8%
Darya-Varia Laboratoria Tbk PT
IDX:DVLA
Accrued Liabilities
Rp372.3B
CAGR 3-Years
9%
CAGR 5-Years
8%
CAGR 10-Years
17%
Soho Global Health Tbk PT
IDX:SOHO
Accrued Liabilities
Rp174.4B
CAGR 3-Years
2%
CAGR 5-Years
-2%
CAGR 10-Years
N/A
Pyridam Farma Tbk PT
IDX:PYFA
Accrued Liabilities
Rp98.5B
CAGR 3-Years
101%
CAGR 5-Years
89%
CAGR 10-Years
48%
No Stocks Found

Kimia Farma Tbk PT
Glance View

Market Cap
3.3T IDR
Industry
Pharmaceuticals

PT Kimia Farma Tbk engages in the production and distribution of healthcare products. The company is headquartered in Jakarta, Dki Jakarta and currently employs 11,668 full-time employees. The company went IPO on 2001-07-04. The firm produces medical devices and chemical materials. The firm is also involved in producing vegetable oil, iodine, and salts. Its products include Glucokaf, Diazink, Oracef, Kifarox, Magacid Suspension, Magaside Chewable Tablets, Nitrocafe Retarded, Nitrocafe Retard Forte, Trinolon, Raistine, VAGIZOL, Neviral, Hiviral Tablet, Duviral, Codipront Cum Expectorant, RETHAPHYL SR, and SUPRAFLU. Its generic products include PETHIDIN Hcl, PARACETAMOL, Diclofenac Sodium, MEPHANAMIC ACID, ANTALGIN, ANTASIDE DOEN, PYRANTEL, ALBENDAZOLE, METRONIDAZOLE TABLET, NEO BLOOD ADDING TABLET, FERROUS SULOATE SYRUP, DIMENHYDRINATE, ACYCLOVIR, AMBROXOL HCL, CHLOROQUINE, CHLORPROMAZINE HCL, CODEIN, CLOPIDOGREL, ERGOTAMINE COFFEE, METHYLERGOMETRINE TABLET SALUTE, MELOXICAM, and Pherphenazine.

KAEF Intrinsic Value
1 038.26 IDR
Undervaluation 42%
Intrinsic Value
Price

See Also

What is Kimia Farma Tbk PT's Accrued Liabilities?
Accrued Liabilities
513.5B IDR

Based on the financial report for Sep 30, 2024, Kimia Farma Tbk PT's Accrued Liabilities amounts to 513.5B IDR.

What is Kimia Farma Tbk PT's Accrued Liabilities growth rate?
Accrued Liabilities CAGR 10Y
24%

Over the last year, the Accrued Liabilities growth was 533%. The average annual Accrued Liabilities growth rates for Kimia Farma Tbk PT have been 59% over the past three years , 28% over the past five years , and 24% over the past ten years .

Back to Top